Nope, they stopped the ET trial at 20 pts. So other than setting-up ISTs in AML and MDS and monitoring the MF IST, they aren't doing anything. About the only good news in this scenario is that they aren't wasting the $90M chasing solid tumors.
I suppose its a good thing they are letting others do the exploratory trials on their own dime (and not GERN's), however, this calls into the question some analysts brought up on the call: so, what exactly are these guys getting paid several hundreds of thousands of dollars in salaries to do, for the next 12 months?
Market Data 
Markets 
AI
